 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...147148149150151152153154155156157...859860» |
- | Ibrance (palbociclib) / Pfizer
New P1/2 trial: A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i (clinicaltrials.gov) - Jul 20, 2023
P1/2, N=32, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Enbrel (etanercept) / Pfizer, Amgen
New P1 trial: RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant (clinicaltrials.gov) - Jul 20, 2023
P1, N=20, Enrolling by invitation, Sponsor: Northwestern University
- |||| Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Enrollment open, Trial initiation date: REMODEL-CD: Precise Infliximab Exposure and Pharmacodynamic Control (clinicaltrials.gov) - Jul 20, 2023
P2/3, N=180, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jul 2023
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Rituxan (rituximab) / Roche
Enrollment open, Trial initiation date: Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jul 20, 2023
P2, N=27, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jul 2023 Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Jul 2023
- | Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / BMS
Enrollment closed, IO biomarker: NCI#10057: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (clinicaltrials.gov) - Jul 20, 2023
P2, N=68, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Jul 2023 Recruiting --> Active, not recruiting
- || zetomipzomib (KZR-616) / Kezar
Trial completion: Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. (clinicaltrials.gov) - Jul 20, 2023
P2, N=18, Completed, Sponsor: Kezar Life Sciences, Inc.
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Journal: Weight-based vs fixed dosing of darbepoetin alfa for anemia following kidney transplantation. (Pubmed Central) - Jul 20, 2023
Enrolling by invitation --> Completed Weight-based and fixed dosing approaches for darbepoetin alfa were not different in the achievement of a hemoglobin concentration of at least 10
- | Ibrance (palbociclib) / Pfizer
Journal: Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper. (Pubmed Central) - Jul 20, 2023
The intracellular inhibition of CDK4/6 by 17m was confirmed by western blot analysis of the levels of phosphorylated Rb in MDA-MB-453 cells. With respect to the metabolic stability, compound 17m possessed longer half-life (t) in mouse liver microsome than palbociclib.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Histopathological response to denosumab in giant cell tumours of bone - A review of 11 cases. (Pubmed Central) - Jul 20, 2023
There may be complete resolution or may be confused with benign or malignant lesions Rarely they may show sarcomatous transformation. It is imperative that the pathologist is aware of these changes to prevent diagnostic pitfalls as it poses therapeutic and prognostic implications.
- | Stivarga (regorafenib) / Bayer
Journal, Metastases: Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib. (Pubmed Central) - Jul 20, 2023
Metastatic CRC patients with high pretreatment PNI and primary tumor resected are more likely to have longer OS with regorafenib. PNI is more reliable index than NLR to predict OS in metastatic CRC patients treated with regorafenib.
- | ivabradine / Generic mfg.
Journal: Effect of preoperative ivabradine on hemodynamics during elective off-pump CABG. (Pubmed Central) - Jul 20, 2023
It helps to maintain a lower HR during surgery and reduces the need for beta-blockers in the intraoperative period, a desirable and beneficial effect in situations where the use of beta-blockers may be potentially harmful. Further studies are needed to evaluate the beneficial effects of perioperative Ivabradine in patients with moderate-to-severe left ventricular dysfunction.
- | oprozomib (ONX 0912) / Amgen
Preclinical, Journal: A Reliable and Effective UPLC-MS/MS Method for the Determination of Oprozomib in Rat Plasma. (Pubmed Central) - Jul 20, 2023
Moreover, the recovery was determined to be from 85.1% to 96.1%, and the values of matrix effect were no more than 110.4%. The optimized UPLC-MS/MS method was also suitable for the pharmacokinetic study of rats after a single oral administration of 21?mg/kg oprozomib.
- | Camzyos (mavacamten) / BMS, omecamtiv mecarbil (AMG 423) / Amgen, Servier, Sutent (sunitinib) / Pfizer
Journal: Reproducibility of drug-induced effects on the contractility of an engineered heart tissue derived from human pluripotent stem cells. (Pubmed Central) - Jul 20, 2023
Reproducibility of drug-induced effects in EHTs between experiments and relative to published work on these cellular models was generally observed. Future applications for EHTs may require additional mechanistic criteria related to drug effects and cardiac functional outputs to be measured in regard to specific contexts of use.
- Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
Final Results of RENOBATE: Multicenter Phase 2 Trial of First-Line Regorafenib Plus Nivolumab for Unresectable Hepatocellular Carcinoma (uHCC) () - Jul 20, 2023 - Abstract #APPLE2023APPLE_347;
There were no unexpected safety signals and most of toxicities were manageable. Biomarker analysis is ongoing.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Real-World Efficacy and Safety of Cabozantinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis () - Jul 20, 2023 - Abstract #APPLE2023APPLE_340;
Prior to cabozantinib, all patients were treated with other systemic therapies: sorafenib (n=104, 94.5%) and regorafenib (n=91, 82.7%) were the most commonly used agents... Cabozantinib showed consistent efficacy outcomes with prior phase III trial, although this was used as later-line therapy for patients who were refractory to multiple systemic treatments, including immune checkpoint inhibitors.
- Evolution of APPLE and Liver Cancer Management () - Jul 20, 2023 - Abstract #APPLE2023APPLE_228;
According to the Japanese nationwide registry of systemic therapy for HCC named Hepatoma Registry of Integrating and Aggregating Electric Health Records (HERITAGE), 6,400 treatment lines (sorafenib 2,319, lenvatinib 2,559, atezolizumab plus bevacizumab 768, regorafenib 406, ramucirumab 251, cabozantinib 71) have been identified in 4,307 cases treated between 2015 and 2022 (Asaoka 2023 ASCO- GI)...Real-world big data analytics using artificial intelligence (AI) may be a future promising direction. APPLE Association will continue to provide an ideal platform to facilitate the exchange of international and regional expertise in the research and management of liver cancer.
- | ivabradine / Generic mfg.
Journal: Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study. (Pubmed Central) - Jul 20, 2023
Ivabradine might be a useful option to relieve symptoms of tachycardia in COVID-19 POTS. Further research is required to confirm the safety and efficacy of ivabradine in POTS treatment.
- | ivabradine / Generic mfg.
Retrospective data, Journal: Ivabradine effects in hospitalized acute heart failure patients: a single center retrospective study. (Pubmed Central) - Jul 20, 2023
Ivabradine was associated with significantly lower average HR and length of hospital stay. However, there was no benefit in the reduction of rehospitalization and mortality rates at 1- and 6-month follow-ups.
- ||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Adverse events: @WesElyMD @thanh_neville @SciImmunology Not asking for personal medical advice, just wondering if you have any experience with adverse events from Tezspire that fall more along the lines of what I typically experience with anaphylaxis to mAb versus the >3% AE reported in doc info (Twitter) - Jul 19, 2023
- | Ibrance (palbociclib) / Pfizer
Journal, Metastases: Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. (Pubmed Central) - Jul 19, 2023
Finally, in ER?+?BC patients, high expression of OXPHOS associated genes predict poor prognosis. In conclusion, these results identify OXPHOS as a promising target for treatment resistant ER?+?BC patients.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, Drug adherence, Adherence: Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients. (Pubmed Central) - Jul 19, 2023
Our study highlights the benefits of a proper time interval of denosumab administration. These findings provide important insight into management of osteoporotic hip fractures and may inform clinical practice and development of guidelines.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Skeletal response to teriparatide in real-life setting: effects of age, baseline bone density and prior denosumab use. (Pubmed Central) - Jul 19, 2023
TPD-induced changes in BMD at TH might depend on age and baseline BMD and at LS on prior denosumab use. The results suggest that these factors may be relevant for clinical decision making when initiating TPD treatment, although larger studies are needed to confirm these findings.
- | SB202190 / Amgen
Preclinical, Journal: Distinct Effects of Mitochondrial Na/Ca Exchanger Inhibition and Ca Uniporter Activation on Ca Sparks and Arrhythmogenesis in Diabetic Rats. (Pubmed Central) - Jul 19, 2023
Conclusions [Ca] is reduced in myocytes from rats with T2D due to a combination of exacerbated mitochondrial Ca extrusion through mitoNCX and impaired mitochondrial Ca uptake. Partial mitoNCX inhibition limits sarcoplasmic reticulum Ca leak and arrhythmias in T2D hearts, whereas mitochondrial Ca uniporter activation does not.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of tezepelumab in Canada for severe asthma. (Pubmed Central) - Jul 19, 2023
P3
Tezepelumab provided additional life years and QALYs at additional cost compared with SoC in Canada. In addition, tezepelumab dominated (i.e., more effective, less costly) the other currently reimbursed biologics.
- ||| Lumakras (sotorasib) / Amgen
Preclinical, Journal, Adverse events: Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson-Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis. (Pubmed Central) - Jul 18, 2023
Of all the best-docked iridoids, Loganic acid passed Lipinski, Pfizer, and GSK filters with a similar toxicity profile to Sotorasib. Thus, if we consider these iridoids to be KRAS G12C inhibitors, they will be a boon to mankind.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner. (Pubmed Central) - Jul 18, 2023
Our findings highlight hidden effects of palbociclib on the dynamics of DNA replication and of its cytotoxic consequences on cell viability in the absence of pRb. This study provides a potential therapeutic application of palbociclib in combination with other drugs to target genomic instability in pRB-deficient cancers.
- || Clinical, Retrospective data, Review, Journal: Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials. (Pubmed Central) - Jul 18, 2023
This study provides a potential therapeutic application of palbociclib in combination with other drugs to target genomic instability in pRB-deficient cancers. No abstract available
- ||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal, Adverse events: Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study. (Pubmed Central) - Jul 18, 2023
No abstract available No abstract available
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia. (Pubmed Central) - Jul 18, 2023
The technique is easy to implement in diagnostic and monitoring workflows, as it does not require isolation of a large number of cells and knowledge of individual clonal rearrangements. We believe it provides important information for further treatment.
- || Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
P2 data, Journal, Metastases: Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder. (Pubmed Central) - Jul 18, 2023
Our study showed substantial efficacy and safety of ddMVAC, even in patients with locally advanced UC. The ddMVAC still should be a promising option as NAC in Asian patients with UC.
- || omecamtiv mecarbil (AMG 423) / Amgen, Servier, istaroxime (PST 2744) / Windtree Therap
Review, Journal: The current and future status of inotropes in heart failure management. (Pubmed Central) - Jul 17, 2023
Therefore, individualized and evidence-based treatment plans for patients who require inotropic support are necessary. Also, better quality data on the use of existing inotropes is imperative, while the development of newer and safer agents will lead to more effective management of patients with HF in the future.
- | Ibrance (palbociclib) / Pfizer, barasertib (AZD1152) / AstraZeneca
Journal, Tumor mutational burden, Gene Signature, Machine learning: Construction of a hepatocytes-related and protein kinase-related gene signature in HCC based on ScRNA-Seq analysis and machine learning algorithm. (Pubmed Central) - Jul 17, 2023
Treatment with Palbociclib (CDK4 Inhibitor) and Barasertib (AURKB Inhibitor) inhibited HCC cell migration. Additionally, the PKRG high-risk group demonstrated higher infiltration levels of Na
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Real-world evidence, Real-world, Metastases: Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy. (Pubmed Central) - Jul 17, 2023
Dose reduction was associated with drug wastage in palbociclib and abemaciclib-treated patients, but not in ribociclib-treated ones. These findings might be helpful to policy decision-makers who, for healthcare strategies implementation, among several variables should consider the possible restraining of drug wastage.
- | Ibrance (palbociclib) / Pfizer, thapsigargin / University of Nottingham, Pirbright Institute
Journal, Tumor mutational burden, IO biomarker: A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses. (Pubmed Central) - Jul 17, 2023
We divided all LUAD patients into two populations with different prognoses. The good prognosis population was sensitive to immunotherapy, while the people with poor prognosis benefitted from 7 drugs.
- || Praluent (alirocumab) / Sanofi, Regeneron, Leqvio (inclisiran) / Alnylam, Novartis, Repatha (evolocumab) / Amgen, Astellas
Review, Journal: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control. (Pubmed Central) - Jul 17, 2023
Additionally, several novel strategies to target PCSK9 are in development, including oral antibody, gene silencing, DNA base editing and vaccine therapies. This review highlights the efficacy, safety and clinical use of these various approaches in PCSK9 inhibition.
- || Review, Journal, IO biomarker: How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication? (Pubmed Central) - Jul 17, 2023
A class of drugs, tyrosine-kinase inhibitors (TKI), targeting mutated FLT3, is already available with 1 and 2 generation molecules, but only midostaurin and gilteritinib are currently approved...Indeed, FLT3 inhibitors have significantly contributed to reducing the negative impact of FLT3 mutations on the prognosis of AML patients who are no longer considered at high risk by the European LeukemiaNet (ELN) 2022. Finally, several ongoing efforts to overcome resistance to FLT3-inhibitors will be presented: new generation FLT3 inhibitors in monotherapy or combined with standard chemotherapy, hypomethylating drugs, or IDH1/2 inhibitors, Bcl2 inhibitors; novel anti-human FLT3 monoclonal antibodies (e.g., FLT3/CD3 bispecific antibodies); FLT3-CAR T-cells; CDK4/6 kinase inhibitor (e.g., palbociclib).
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Journal: Allogeneic haematopoietic cell transplants as dynamical systems: influence of early-term immune milieu on long-term T-cell recovery. (Pubmed Central) - Jul 17, 2023
The long-term superior immune recovery in the MMF15 arm, administered GMCSF, is consistent with a disproportionate impact of early interventions in HCT. Modifying the 'immune-milieu' following allogeneic HCT is feasible and may influence long-term T-cell recovery.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Observational data: Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone-Modifying Agents for Bone Metastases: A Cross-Sectional Study. (Pubmed Central) - Jul 17, 2023
Modifying the 'immune-milieu' following allogeneic HCT is feasible and may influence long-term T-cell recovery. Forty-two patients (23 men, 19 women; mean age 68.8?
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine. (Pubmed Central) - Jul 17, 2023
JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
- || Repatha (evolocumab) / Amgen, Astellas, rosuvastatin / Generic mfg.
My Lipoprotein Fractional Ion Mobility blood test showing my LDL-P at 1407 was when I was on Crestor for 3 years. My LDL-C was 67. Stains don't lower small dense LDL particles much. They lower more of the Large fluffy LDL particles. Repatha does lower small LDL particles. (Twitter) - Jul 17, 2023
- | Ibrance (palbociclib) / Pfizer
Observational data, Retrospective data, Journal, Combination therapy, Real-world evidence, Real-world, Metastases: Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer. (Pubmed Central) - Jul 17, 2023
P=N/A
on behalf of American Society for Bone and Mineral Research. This real-world analysis suggests that pre/perimenopausal patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer appear more likely to respond to palbociclib plus AI versus AI alone as first-line therapy, which may support the combination as a standard-of-care treatment for this patient population.
- || efruxifermin (AKR-001) / Amgen
Review, Journal: Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH). (Pubmed Central) - Jul 17, 2023
While some other FGF-21 agonists (e.g. pegbelfermin) are currently not further investigated, available evidence supports the development of EFX as a promising anti-NASH drug in fibrotic and cirrhotic populations. However, antifibrotic efficacy, long-term safety and benefits (i.e. cardiovascular risk, decompensation events, disease progression, liver transplantation, mortality) remain to be determined.
- | Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Visual hypersensitivity in patients treated with anti-calcitonin gene-related peptide (receptor) monoclonal antibodies. (Pubmed Central) - Jul 17, 2023
However, antifibrotic efficacy, long-term safety and benefits (i.e. cardiovascular risk, decompensation events, disease progression, liver transplantation, mortality) remain to be determined. A decrease in visual hypersensitivity in patients with migraine after treatment with anti-CGRP (receptor) antibodies is positively associated with clinical response on migraine.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Retrospective data, Journal, Metastases: The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study. (Pubmed Central) - Jul 17, 2023
A decrease in visual hypersensitivity in patients with migraine after treatment with anti-CGRP (receptor) antibodies is positively associated with clinical response on migraine. Low HER2 expression did not significantly impact treatment response or PFS in HR+
- | Ibrance (palbociclib) / Pfizer
Journal: Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor. (Pubmed Central) - Jul 17, 2023
Hormone receptor-positive, HER2-negative advanced breast cancers exhibit high sensitivity to CDK4/6 inhibitors such as palbociclib...Overall, our pre-clinical data identifies activated ACK1 as an oncogene that epigenetically controls the cell cycle genes governing the G2/M transition in breast cancer cells. ACK1 inhibitor, (R)-9b could be a novel therapeutic option for the breast cancer patients that have developed resistance to CDK4/6 inhibitors.
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Review, Journal: TNF? inhibitor biosimilar associated with polychondritis. A case-based review. (Pubmed Central) - Jul 17, 2023
ACK1 inhibitor, (R)-9b could be a novel therapeutic option for the breast cancer patients that have developed resistance to CDK4/6 inhibitors. This report presents a 43-year-old man with psoriatic arthritis treated with ABP-501 (Amgevita), an adalimumab (ADA) biosimilar and who developed RP, 8
- ||| Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Journal, Adverse events: Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. (Pubmed Central) - Jul 17, 2023
Most of chemotherapy-related AEs (except for HFS and neuropathy) reach the highest level in the first cycles, then decrease, probably due to their active clinical management. Transition to maintenance allows relief from most AEs, especially with bevacizumab-based regimens, while anti-EGFR-related AEs may persist.
- ||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo
Journal, Adverse events: Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data. (Pubmed Central) - Jul 17, 2023
AI could significantly ease some of the most time-consuming and labor-intensive steps of signal detection and validation. The AI-based approach showed promising results, however, future work is needed to validate the framework.
- | Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Retrospective data, Journal, HEOR, Real-world evidence, Real-world: Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence. (Pubmed Central) - Jul 17, 2023
The AI-based approach showed promising results, however, future work is needed to validate the framework. To compare patients with primary immune thrombocytopenia (ITP) prescribed early (within 3
- | Journal: Incident psoriasis under treatment with tumor necrosis factor-? inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry. (Pubmed Central) - Jul 17, 2023
JIA patients receiving monoclonal antibody TNFi or non-TNFi bDMARD should be monitored for incident psoriasis. Medication change, if topical skin treatment remains insufficient, may be considered.